glp1 retatrutide 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Unapproved weight loss drug retatrutide

et al., The increasing rate of diabetes in Pakistan: A silent killer (2022) IDF, Prevalence of Diabetes in Pakistan (2024) Jastreboff et al., NEJM, Phase 2 obesity trial of retatrutide (2023) Reuters Next generation Lilly weight-loss drug shows added heart, liver benefits (2024) Investopedia / news20 Eli Lilly shares rise after drug helps patients lose more weight than competitors (2023) Lancet Phase 2 trial on T2DM (via ResearchGate summary) PMC meta-analysis: weight/metabolic outcomes of retatrutide Anti-obesity medication (retatrutide entry) News21 (Axios) Extraordinary promise of retatrutide (2023) USA Today (American Diabetes Association summary) News25 (NY Post) re: Phase 3 status and side effects

Red Flags to Watch For If you or a loved one is taking or considering a GLP-1 medication, its important to stay mindful of potential early warning signs that recovery may be at risk

Beyond helping you lose weight and keep your blood sugar under control, these drugs have also been shown to improve your blood pressure and cholesterol numbers and lower your heart disease risk

This may be altered throughout your weight loss journey to maintain optimal health and consistent results

Discover how it affects weight loss, side effects, and your health when taking this GLP-1 medication